We will report 2 cases of posttraumatic neck syndrome being successfully treated with Hochu-ekki-to and Goreisan.
A 52-and a 47-year-old women suffered the posttraumatic neck syndrome (whiplash injury) by the traffic accident. They did not respond to NSAIDs (nonsteroidal anti-inflammatory drugs) for several months. According to the “Shou” (“Kikyo” and “Suitai”) of these patients, we prescribed Hochu-ekki-to and Goreisan.
Whiplash injury is a soft tissue injury of the neck, and said to be “Oketsu” because the presence of the internal hemorrhage in the soft tissue is believed. But we did not find “Oketsu” in our 2 cases. Chronic pain patients are often “Kikyo”, thus we assume treatments on “Kikyo” should be effective in posttraumatic neck syndrome.

Hansen's disease (HD) is a chronic infectious disease caused by the Mycobacterium leprae, which parasitizes skin macrophages and Schwann cells of peripheral nerves. Left untreated, leprosy can be progressive, causing permanent damage to the skin, nerves, limbs and eyes due to sensory disturbance and neuritis. Many HD patients suffer from refractory neuralgia for which neither painkillers nor other western medicine are usually effective. Here, we will report the case of an 85 year-old male, whose refractory neuralgia remarkably improved with goreisan. The mechanisms by which goreisan was effective may be as follows : (1) neuralgia pathology is an interstitial edema of peripheral nerves, and can explain as a local Sui-doku, a specific Sho for goreisan ; (2) peripheral nerve ischemia, caused by scar formation from chronic inflammation, leads to dysfunction of Na⁺/K⁺ ATPase, and extracellular potassium concentration increases. This environmental change leads a neural hypersensitivity, and goreisan is known to decrease extracellular potassium concentrations. This case suggests goreisan might be worth considering for use in refractory neuralgia, not only in HD patients, but also in other neuropathies.

1) We have implemented a portfolio as a learning and assessment tool into clinical clerkship rotation focusing on primary care medicine.
2) We received favorable responses both from students and teachers.
3) It is further required to promote the understanding of portfolio among teachers and students to enhance its utilization.

Uterine leiomyosarcoma (ULMS) is one of the most aggressive gynecological malignancies. In the past decade, novel therapeutic agents such as trabectedin and pazopanib have been approved, but the prognosis of patients remains unsatisfactory. This study aimed to identify potential therapeutic targets for ULMS based on transcriptome analysis. Archival fresh-frozen tumor tissues of 6 ULMS and three leiomyoma samples were used in this study, and total RNA was extracted. First, transcriptome analysis identified 512 significantly differentially expressed genes, and subsequent pathway analysis using IPA software revealed that the functions of cell cycle-related kinases were significantly activated in ULMS. Moreover, our results were validated using 3 independent Gene Expression Omnibus datasets, including 40 ULMS. Therefore, we considered the kinases as novel therapeutic targets and evaluated the anti-cancer effects of several selective inhibitors against them. Most inhibitors exerted a higher anti-cancer effect than pazopanib in three leiomyosarcoma cell lines. Especially, CHEK1 or PLK1 inhibitors strongly induced cell cycle arrest and cell death, and the IC50s were lower nanomolar concentration. Moreover, the inhibitors suppressed the tumor growth in SK-UT-1 bearing mice models. In conclusion, we revealed the unique gene expression profiles of ULMS. CHEK1 and PLK1 are promising therapeutic targets for ULMS, and therefore, further clinical trials are highly anticipated to improve the prognosis of the patients.

OBJECTIVES: There is increasing evidence that systemic inflammatory response (SIR) markers are prognostic factors for various types of cancers. This is the first study to evaluate the usefulness of SIR markers for the prognosis of early-stage ovarian clear-cell carcinoma (OCCC). METHODS: We retrospectively investigated 83 patients diagnosed with stage I–II OCCC who underwent surgery between 2005 and 2017. Initially, receiver operating characteristic curve analysis for overall survival (OS) was used to determine optimal cut-off values for neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Patients were stratified into 2 groups by the cut-off values (NLR=3.26, PLR=160). Univariate and multivariate analyses were performed to elucidate the significance of SIR markers as prognostic factors. RESULTS: In the median follow-up period of 64.1 months, 16 patients experienced recurrence, and nine patients died. The Kaplan-Meier curve showed that OS of the NLR-low group was significantly longer than the NLR-high group (p=0.021). There was no significant difference in progression-free survival between the 2 groups (p=0.668), but the post-recurrence survival of the NLR-low group was significantly longer than the NLR-high group (p=0.019). Furthermore, multivariate analysis showed that increase in NLR is a significant independent prognostic factor for poor prognosis (hazard ratio=7.437, p=0.017). There was no significant difference between PLR-low and PLR-high group. CONCLUSION: Results suggest that NLR can be a significant independent prognostic factor for early-stage OCCC.
Adenocarcinoma, Clear Cell ; Biomarkers ; Disease-Free Survival ; Follow-Up Studies ; Humans ; Multivariate Analysis ; Prognosis ; Recurrence ; Retrospective Studies ; ROC Curve

Objective: Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian carcinoma with poor prognosis. However, no effective biomarkers have been established for predicting unfavorable events, including recurrence and poor prognoses. Serum microRNAs (miRNAs) have been increasingly reported to be useful in predicting a patient’s condition and have been recognized as a potentially less-invasive source for liquid biopsy in cancer. Therefore, this study aimed to evaluate serum miRNA profiles from patients with OCCC and to establish biomarker for predicting the prognoses. Methods: The GSE106817, which included preoperative serum miRNA profiles of patients with ovarian tumors, was used, and clinical information was investigated. In all, 66 patients with OCCC were included, excluding those with other histological subtypes or insufficient prognostic information. Moreover, miRNA profiles of OCCC tissues were also examined. Results: The median follow-up period was 64.3 (8.0–153.3) months. Based on multivariable Cox regression analyses and the expression of miRNAs in OCCC tissues, miR-150-3p, miR-3195, and miR-7704 were selected as miRNA candidates associated with both progression-free survival (PFS) and overall survival (OS). Then, the prognostic index was calculated based on expression values of 3 serum miRNAs. Kaplan-Meier survival analysis indicated that the prognostic index was significantly predictive of PFS and OS (p=0.004 and p=0.012, respectively). Conclusion Preoperative serum miRNA profiles of miR-150-3p, miR-3195, and miR-7704 can be used to potentially predict the prognosis of patients with OCCC.